ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release
The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release
Posted in Healthcare, Science, Sweden, Technology, United Kingdom
Tagged assisted ventilation, AstraZeneca, best supportive care, blood cancers, Bruton’s tyrosine kinase, BSC, BTK, BTK inhibitor, CALAVI, Calquence, clinical trial, COVID-19, cytokine storm, exaggerated immune response, inflammatory cytokines, José Baselga, Louis M. Staudt M.D. Ph.D., lung disease
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?